Altre lingue Quince Therapeutics, Inc.

Azioni

QNCX

US22053A1079

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
1,06 ^USD	-4,50%		+6,00%	+0,95%

01/04	Quince Therapeutics, Inc. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
26/03	Transcript : Quince Therapeutics, Inc. - Special Call

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results	01/04
North American Morning Briefing : Markets Steady -2-	26/03
Quince Therapeutics Launches Scientific Advisory Board	22/02
Quince Therapeutics, Inc. Launches Scientific Advisory Board	22/02
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors	15/02
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors	15/02
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference	07/02
Quince Therapeutics to Participate at Investor Events in January 2024	04/01
North American Morning Briefing : All Eyes on -2-	21/11
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Quince Therapeutics : Investor Presentation – November 2023	06/11
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer	26/10/23
Quince Therapeutics, Inc. Appoints Luca Benatti as Director	23/10/23
Quince Therapeutics Completes Acquisition of EryDel S.p.A.	23/10/23
Quince Therapeutics, Inc. acquired EryDel S.p.A	23/10/23
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia	28/09/23
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold	28/09/23
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia	28/09/23
Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug Application for Its Lead Phase 3 Asset, Erydex	28/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Quince Therapeutics, Inc.

Azioni

QNCX

US22053A1079

Altre lingue

Filtri